{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "epsTrailingTwelveMonths": -0.19, "sharesOutstanding": 5234610, "fiftyDayAverage": 2.7925, "fiftyDayAverageChange": -0.14750004, "fiftyDayAverageChangePercent": -0.052820068, "twoHundredDayAverage": 2.237725, "twoHundredDayAverageChange": 0.40727496, "twoHundredDayAverageChangePercent": 0.18200402, "marketCap": 13951449, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "prevName": "Nfl Biosciences", "nameChangeDate": "2023-05-11", "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "currency": "EUR", "regularMarketOpen": 2.66, "averageDailyVolume3Month": 61880, "averageDailyVolume10Day": 39637, "fiftyTwoWeekLowChange": 2.0970001, "fiftyTwoWeekLowChangePercent": 3.8266428, "fiftyTwoWeekRange": "0.548 - 3.58", "fiftyTwoWeekHighChange": -0.93499994, "fiftyTwoWeekHighChangePercent": -0.2611732, "fiftyTwoWeekLow": 0.548, "fiftyTwoWeekHigh": 3.58, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "firstTradeDateMilliseconds": 1625468400000, "priceHint": 4, "marketState": "POSTPOST", "regularMarketChange": 0.029999971, "regularMarketTime": 1683903449, "regularMarketDayHigh": 2.7, "regularMarketDayRange": "2.61 - 2.7", "regularMarketDayLow": 2.61, "regularMarketVolume": 7145, "regularMarketPreviousClose": 2.615, "fullExchangeName": "Paris", "regularMarketChangePercent": 1.1472265, "regularMarketPrice": 2.645, "exchangeTimezoneName": "Europe/Paris", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "esgPopulated": false, "exchange": "PAR", "shortName": "NFL BIOSCIENCES S.A.", "longName": "NFL Biosciences SA", "messageBoardId": "finmb_677036256", "market": "fr_market", "symbol": "ALNFL.PA"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "199 Rue H\u00e9l\u00e8ne Boucher", "city": "Castelnau-le-Lez", "zip": "34170", "country": "France", "phone": "33 4 11 93 76 67", "website": "https://www.nflbiosciences.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "NFL Biosciences SA, a biotechnology company, develops natural addiction withdrawal solutions for smokers. The company's natural drug candidate in pipeline to cure tobacco addiction include NFL-101, a tobacco extract that is in Phase III clinical trial targeting smoking addiction; NFL-201, a cannabis and tobacco extract, which is in preclinical stage; and NFL-301, a botanical extract (traditional Chinese medicine) that is in preclinical stage. NFL Biosciences SA was incorporated in 2006 and is based in Castelnau-le-Lez, France.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Ignacio  Faus M.B.A., Ph.D.", "title": "CEO & Chairman", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Bruno  Lafont M.B.A., M.Sc.", "title": "Co-Founder, COO & Director", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Guillaume  Audema", "title": "Chief Financial Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "maxAge": 86400}}], "error": null}}